|Mr. Ilan Danieli||Founder, Pres, CEO & Director||334.89k||N/A||1972|
|Mr. Carl R. Iberger||CFO & Sec.||302.58k||N/A||1953|
|Mr. Ahmed Zaki Sabet||Chief Operating Officer||168.79k||N/A||1987|
|Mr. Ayman Mohamed M.D.||Sr. VP of R&D and Laboratory Operations||192.11k||N/A||1986|
|Ms. Miri Chiko-Radomski||Gen. Counsel||N/A||N/A||N/A|
|Mr. Douglas Sites||VP of Sales||N/A||N/A||N/A|
|Mr. Ori Karev||Chief Strategy Officer||N/A||N/A||N/A|
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Precipio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.